CO2022004535A2 - Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes - Google Patents

Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes

Info

Publication number
CO2022004535A2
CO2022004535A2 CONC2022/0004535A CO2022004535A CO2022004535A2 CO 2022004535 A2 CO2022004535 A2 CO 2022004535A2 CO 2022004535 A CO2022004535 A CO 2022004535A CO 2022004535 A2 CO2022004535 A2 CO 2022004535A2
Authority
CO
Colombia
Prior art keywords
expression
terminal extension
therapeutic peptides
recombinant therapeutic
extension sequence
Prior art date
Application number
CONC2022/0004535A
Other languages
English (en)
Inventor
Ramesh Venkat Matur
Rajan Sriraman
Pavan Reddy Regatti
Narender Dev Mantena
Mahima Datla
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of CO2022004535A2 publication Critical patent/CO2022004535A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

RESUMEN La invención se relaciona con secuencias de extensión N-terminal las cuales se emplean para mejorar la expresión de péptidos terapéuticos recombinantes. La invención también se relaciona con un proceso para la expresión de alto nivel de péptidos terapéuticos recombinantes usando la secuencia de extensión N-terminal. La invención también proporciona ácidos nucleicos, vectores y células hospederas recombinantes para la producción eficiente de proteínas biológicamente activas como lirapéptido.
CONC2022/0004535A 2019-09-13 2022-04-08 Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes CO2022004535A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941009728 2019-09-13
PCT/IN2020/050790 WO2021048878A1 (en) 2019-09-13 2020-09-12 N-terminal extension sequence for expression of recombinant therapeutic peptides

Publications (1)

Publication Number Publication Date
CO2022004535A2 true CO2022004535A2 (es) 2022-04-29

Family

ID=74866188

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0004535A CO2022004535A2 (es) 2019-09-13 2022-04-08 Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes

Country Status (14)

Country Link
US (1) US20230002468A1 (es)
EP (1) EP4028519A4 (es)
JP (1) JP2022548598A (es)
KR (1) KR20220058631A (es)
CN (1) CN114651063A (es)
AU (1) AU2020345138A1 (es)
BR (1) BR112022004601A2 (es)
CA (1) CA3150902A1 (es)
CO (1) CO2022004535A2 (es)
CU (1) CU20220017A7 (es)
IL (1) IL291127A (es)
MX (1) MX2022003002A (es)
WO (1) WO2021048878A1 (es)
ZA (1) ZA202202579B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4314034A2 (en) * 2021-03-31 2024-02-07 Biological E Limited Constructs and methods for increased expression of polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082671A1 (en) * 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
SG11201405276PA (en) * 2012-02-27 2014-10-30 Amunix Operating Inc Xten conjugate compositions and methods of making same
US20190352365A1 (en) * 2017-01-18 2019-11-21 Savior Lifetec Corporation Expression construct and method for producing proteins of interest
WO2019082138A1 (en) * 2017-10-27 2019-05-02 Lorven Biologics Private Limited PROCESS FOR THE PREPARATION OF LIRAGLUTIDE USING RECOMBINANT SACCHAROMYCES CEREVISIAE
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
CN108218997B (zh) * 2017-12-30 2020-12-15 北京中科唯新生物医学研究所有限公司 一种用于纯化蛋白的表达载体
EP3741774A4 (en) * 2018-01-19 2021-06-02 Pepgene Inc. N-TERMINAL FUSION PARTNER FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID AND PROCESS FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID USING THESE

Also Published As

Publication number Publication date
EP4028519A1 (en) 2022-07-20
US20230002468A1 (en) 2023-01-05
AU2020345138A1 (en) 2022-04-21
CA3150902A1 (en) 2021-03-18
KR20220058631A (ko) 2022-05-09
MX2022003002A (es) 2022-04-07
WO2021048878A1 (en) 2021-03-18
BR112022004601A2 (pt) 2022-05-31
IL291127A (en) 2022-05-01
EP4028519A4 (en) 2023-10-11
ZA202202579B (en) 2022-10-26
CN114651063A (zh) 2022-06-21
CU20220017A7 (es) 2022-10-11
JP2022548598A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
AU2018298422A1 (en) Novel nucleic acid molecules
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
EA202090817A1 (ru) Триспецифические белки и способы их применения
UA120917C2 (uk) Химерний білок фактора viii та його застосування
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MX2019003360A (es) Vectores de expresion para una secrecion de proteina mejorada.
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
NZ724196A (en) Uti fusion proteins
CO2023000048A2 (es) Conjugados de citoquina
MX2010009071A (es) Peptidos aislados que tienen actividad inhibitoria de fosfolipasa.
BR112022006842A2 (pt) Construtos de igf2 variante
MX2022006385A (es) Acidos nucleicos, vectores, celulas huespedes y metodos para la produccion de beta-fructofuranosidasa a partir de aspergillus niger.
ZA202308985B (en) Constructs and methods for increased expression of polypeptides
EA202092065A1 (ru) ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)
MX2018003445A (es) Expresion de proteinas que contienen fc.
EA202091713A1 (ru) Биологический синтез аминокислотных цепей для получения пептидов и белков
CL2022001376A1 (es) Proteínas gpcr de opsinas quiméricas
EA201790362A1 (ru) Солюбилизированный фермент и его применения
RU2014137557A (ru) Способ получения биологически активных пептидов
EA201991195A1 (ru) Мультимерные полипептиды, модулирующие т-клетки, и способы их применения
EA202190853A1 (ru) Связывающие dll3 белки и способы применения
EA202192299A1 (ru) Библиотеки вариантных нуклеиновых кислот для оптимизации антител